Allergan Aesthetics Announces Topline Results From Second Phase 3 Study Of OnabotulinumtoxinA (Botox Cosmetic) For The Treatment Of Platysma Prominence; All Primary And Secondary Endpoints Were Met
Portfolio Pulse from Benzinga Newsdesk
Allergan Aesthetics, a subsidiary of AbbVie (NYSE:ABBV), announced positive results from the second Phase 3 study of onabotulinumtoxinA (Botox Cosmetic) for the treatment of platysma prominence. The study met all primary and secondary endpoints, supporting the drug as a potential treatment option. The data will be included in a regulatory submission to the U.S. Food and Drug Administration expected by the end of the year.
September 18, 2023 | 1:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AbbVie's Allergan Aesthetics reports positive results from a Phase 3 study of Botox Cosmetic for platysma prominence. This could potentially expand AbbVie's product portfolio and generate additional revenue if approved by the FDA.
The positive results from the Phase 3 study of Botox Cosmetic for platysma prominence could potentially lead to FDA approval. If approved, this would expand AbbVie's product portfolio and could generate additional revenue. The news is highly relevant to AbbVie as it directly pertains to one of their products and could have a significant impact on their financial performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100